Nonsense Mediated Decay Resistant Mutations Are a Source of Expressed Mutant Proteins in Colon Cancer Cell Lines with Microsatellite Instability by Williams, David S. et al.
Nonsense Mediated Decay Resistant Mutations Are a
Source of Expressed Mutant Proteins in Colon Cancer
Cell Lines with Microsatellite Instability
David S. Williams
1,2,3*, Matthew J. Bird
1, Robert N. Jorissen
4, Yen Lin Yu
1, Franscesa Walker
1, Hui Hua
Zhang
1, Edouard C. Nice
1, Antony W. Burgess
1,4*
1Epithelial Biochemistry Laboratory, Ludwig Institute for Cancer Research, Melbourne Branch, Parkville, Victoria, Australia, 2Department of Pathology, University of
Melbourne, Parkville, Victoria, Australia, 3Department of Anatomical Pathology, Melbourne Health, Parkville, Victoria, Australia, 4Ludwig Colon Cancer Initiative
Laboratory, Ludwig Institute for Cancer Research, Melbourne Branch, Parkville, Victoria, Australia
Abstract
Background: Frameshift mutations in microsatellite instability high (MSI-High) colorectal cancers are a potential source of
targetable neo-antigens. Many nonsense transcripts are subject to rapid degradation due to nonsense-mediated decay
(NMD), but nonsense transcripts with a cMS in the last exon or near the last exon-exon junction have intrinsic resistance to
nonsense-mediated decay (NMD). NMD-resistant transcripts are therefore a likely source of expressed mutant proteins in
MSI-High tumours.
Methods: Using antibodies to the conserved N-termini of predicted mutant proteins, we analysed MSI-High colorectal
cancer cell lines for examples of naturally expressed mutant proteins arising from frameshift mutations in coding
microsatellites (cMS) by immunoprecipitation and Western Blot experiments. Detected mutant protein bands from NMD-
resistant transcripts were further validated by gene-specific short-interfering RNA (siRNA) knockdown. A genome-wide
search was performed to identify cMS-containing genes likely to generate NMD-resistant transcripts that could encode for
antigenic expressed mutant proteins in MSI-High colon cancers. These genes were screened for cMS mutations in the MSI-
High colon cancer cell lines.
Results: Mutant protein bands of expected molecular weight were detected in mutated MSI-High cell lines for NMD-
resistant transcripts (CREBBP, EP300, TTK), but not NMD-sensitive transcripts (BAX, CASP5, MSH3). Expression of the mutant
CREBBP and EP300 proteins was confirmed by siRNA knockdown. Five cMS-bearing genes identified from the genome-wide
search and without existing mutation data (SFRS12IP1, MED8, ASXL1, FBXL3 and RGS12) were found to be mutated in at
least 5 of 11 (45%) of the MSI-High cell lines tested.
Conclusion: NMD-resistant transcripts can give rise to expressed mutant proteins in MSI-High colon cancer cells. If
commonly expressed in primary MSI-High colon cancers, MSI-derived mutant proteins could be useful as cancer specific
immunological targets in a vaccine targeting MSI-High colonic tumours.
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Introduction
Approximately 15% of colorectal, gastric and endometrial
cancers have defective DNA mismatch repair and high-level
microsatellite instability (MSI-High)[1,2]. Most MSI-High tu-
mours result from sporadic hypermethylation of the MLH1 gene
promoter[3], but mutation of a DNA mismatch repair enzyme is
the underlying defect in cases of hereditary non-polyposis
colorectal cancer (HNPCC)[4]. Tumours with MSI have a form
of genetic instability that manifests as frameshift mutations in
repetitive microsatellite sequences of DNA[1]. Frameshift muta-
tions in coding microsatellites (cMS) alter the genetic reading
frame and in most instances encode for truncated proteins with
unique C-terminal protein sequences.
An intriguing pathological feature of MSI-High colorectal
cancers is a tendency to have increased numbers of tumour
infiltrating lymphocytes (TILs) relative to MSI-Low and micro-
satellite stable (MSS) tumours[5]. The TILs in MSI-High tumours
are activated CD8+ cytotoxic T lymphocytes (CTLs)[6], suited to
recognising intracellular peptides such as MSI-derived neo-
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phenotype and increased TILs in a colorectal cancer connote a
better stage-matched prognosis relative to MSI-Low or MSS
tumours[7,8]. This survival advantage may reflect a protective
benefit of the immune infiltrate[9].
Synthetic peptides corresponding to mutant proteins predicted
to arise from MSI-associated frameshift mutations have been
shown to be immunogenic. Over the past decade, cytotoxic T
lymphocyte (CTL) responses have been described against HLA-A2
binding peptides arising from frameshift mutations in the A10
cMS of TGFBR2[10,11], the A10 cMS of CASP5[12], the T10
cMS of OGT[13] and recently the T15 cMS of U79260
(FTO)[14]. CTL responses to mutant proteins have been detected
in patients with MSI associated colon cancers and in healthy
HNPCC-mutation carriers, raising the possibility of protective
immunosurveillance in the latter population[15].
There is published mutation data available for at least 1522
mononucleotide coding microsatellites from 460 genes in MSI-
High colorectal cancers[16]. A correlation exists between cMS
length and mutation rate. Genes with cMS mutations are potential
sources of targetable proteins for immune therapy strategies. Since
frameshift mutations affect cMS repeats in a predictable manner,
the mutant proteins generated are likely to be conserved in a
population of patients with MSI-High colon cancers[17,18].
Although no one mutant transcript is common to all MSI-High
tumours, a vaccine that targets a set of commonly mutated
proteins may be an effective treatment for MSI-High colon
cancers. There is a need for new therapies against MSI-High colon
cancers, since multiple studies have shown these tumours to be
resistant to standard chemotherapeutics such as 5-fluoroura-
cil[19,20,21].
The existence of MSI-derived mutant proteins has been inferred
by immunological studies, but there is a lack of published data
regarding the direct detection of the predicted MSI-derived
mutant proteins. Western blot analyses have been published in
which potential mutant protein bands were detected for the
CREBBP, EP300 [22] and MBD4 genes [23], but there was no
validation of these bands. Confirming the expression of mutant
proteins in MSI-High tumours is important if these are to be
successful therapeutic targets for a vaccine. Stable expression of
mutant proteins which facilitates cross presentation of tumour
antigens by professional antigen presenting cells and stimulates a T
helper response is likely to provide superior anti-tumour
immunity[18]. However, most mutant transcripts generated by
MSI are targeted for rapid degradation by nonsense-mediated
decay (NMD)[24,25] and in the absence of intervention, little to
no targetable mutant protein will be generated from these aberrant
transcripts[24].
In this study we have detected three MSI-derived mutant
proteins, all of which arise from NMD-resistant transcripts.
Following a genome-wide search for additional NMD-resistant
transcripts, cMS-containing genes were screened for mutations in
a panel of 11 MSI-High colon cancer cell lines. Genes were
selected for mutation analysis on the basis of likely high mutation
frequency (based on cMS length), likely immunogenicity (based on
mutant C-terminus amino acid length) and likely expression in
colon cancer (based on gene and protein expression data where
available). Commonly mutated NMD-resistant transcripts were
assessed for probable HLA-A*0201 CTL epitopes using in silico
predictive software, SYFPEITHI[26], for comparison with MSI-
derived epitopes already shown to be immunogenic in vitro.
Our results confirm that NMD-resistant transcripts give rise to
expressed mutant proteins and also show that commonly occurring
frameshift mutations that generate NMD-resistant transcripts are a
promising source of targetable tumour antigens in MSI-High
colon cancers. A set of commonly expressed mutant proteins has
the potential to form the basis for a multivalent vaccine or
immunotherapeutic targeting MSI-High tumours.
Results
MSI-High colon cancer cell lines harbor frameshift
mutations in multiple cMS
Screening of the colon cancer cells lines for aberrant expression
DNA mismatch repair proteins revealed an abnormal phenotype
consistent with MSI in 11 of 17 cell lines (Table 1). The cell lines
were assessed for frameshift mutations in a selection of genes with
cMS previously reported to develop mutations in MSI-High colon
cancers. Numerous mutations consistent with an MSI-High
phenotype were detected in each cell line with aberrant DNA
mismatch repair expression by immunohistochemistry, but few
mutations if any were detected in the remaining cell lines (Table 2,
Table S1). Deletion of 1 DNA base pair was the most common
mutation, accounting for 82% (214/262) of the mutations
observed in this study (probable biallelic mutations counted as 2
mutations). Most frameshift mutations encode for truncated
proteins of lower molecular weight with a mutated C-terminus
(Table 3).
Detectable MSI-derived mutant proteins are expressed
by NMD-resistant transcripts
To detect expressed mutant proteins, we purchased antibodies
to the conserved N-terminal portion of selected proteins. We
initially studied a selection of commonly mutated genes reported
to be potential ‘‘target genes’’[1]. Western blot experiments on
whole cell lysates and immunoprecipitates of the genotyped cell
lines identified protein bands corresponding to the expected
molecular weight for normal BAX (Figure 1), MSH3 and CASP5
proteins (unpublished data) in cell lines with non-mutated alleles of
Table 1. Assessment of cell lines for MSI status by IHC.
Cell line
MSI
status MLH1 PMS2 MSH2 MSH6 Reference
SW1222 MSS normal - normal normal [52]
SW480 MSS normal - normal normal [52]
LIM1863 MSS normal normal normal normal [47]
LIM2099 MSS normal normal normal normal [49]
LIM2463 MSS normal normal normal normal [48]
HT29 MSS normal - normal Normal [53]
HCA-7 MSI absent - normal normal [54]
HCT116 MSI absent - normal normal [55]
LoVo MSI normal - absent absent [56]
LS174T MSI absent - normal normal [57]
LIM1215 MSI absent - normal normal [45]
LIM1899 MSI normal absent normal normal [46]
LIM2405 MSI absent absent normal normal [49]
LIM2408 MSI absent absent normal normal [49]
LIM2537 MSI absent absent normal normal [49]
LIM2550 MSI absent absent normal normal [49]
LIM2551 MSI absent absent normal normal [49]
doi:10.1371/journal.pone.0016012.t001
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any of these genes. In the case of BAX we generated polyclonal
rabbit antibodies to a synthetic peptide corresponding to the
mutated C-terminus. These antibodies showed specific binding to
synthetic mutant peptide in Biacore, ELISA and Western blot
assays, but did not detect a mutant BAX protein band in whole
cell lysates or immunoprecipitates of BAX mutated cell lines
(unpublished data). Mutations in BAX, MSH3 and CASP5 all
encode for NMD-sensitive (NMD-S) mutant transcripts; mutant
BAX and MSH3 are known to be susceptible to degradation[27].
NMD-sensitivity could account for our inability to detect any
mutant proteins arising from these three genes, though abnormal
protein folding with loss of the antibody epitopes might also be a
factor.
We therefore sought to detect mutant proteins arising from
NMD-resistant (NMD-R) transcripts. Previously published West-
ern blot data showed potential mutant protein bands of the
CREBBP and EP300 genes, each arising from a heterozygous (21,
wild type) frameshift mutation of a 5 mer cMS repeats in the last
exon, detected in the LoVo (CREBBP) and HCT116 (EP300) cell
lines respectively[22]. We confirmed the presence of these
mutations in LoVo and HCT116 cell lines by PCR and DNA
sequencing. These cMS were not mutated in any of the other
MSI-High or MSS cell lines. Bands corresponding to the expected
molecular weights of the normal CREBBP and EP300 protein
were consistently detected in Western blot analyses of non-
mutated cell lines. We detected abnormal protein bands
corresponding to the expected molecular weights of mutant
CREBBP and mutant EP300 in the LoVo and HCT116 cell lines
respectively in Western Blots on whole cell lysates (Figure 2) and
on immunoprecipitates (Figure S1). Our blot matched the
previously published data for EP300[22]. The prior CREBBP
data matched a region of non-specific bands in our blot, but
protein bands of appropriate molecular weight were also present in
our blots. The CREBBP bands were also detected in experiments
where one antibody was used for an immunoprecipitation and an
antibody to a different CREBBP epitope was used for detection.
Validation of the mutant proteins
To confirm the identity of the abnormal protein bands and
prove that these represent genuine examples of the expected
mutant proteins, we initially performed tandem mass spectrometry
on immunoprecipitates of the cell lines. This technique confirmed
the identity of the normal CREBBP and EP300 protein bands
(Figure S1), thus validating the specificity of the antibodies used.
The mutant proteins were not detected by this method, possibly
due to co-immunoprecipitation of more abundant proteins of
similar molecular weight such as MYH9 (unpublished data). The
specificity of the mutant protein bands was instead confirmed by
using small interfering RNA (siRNA) to perform gene specific
knockdowns of the mutant CREBBP and EP300 proteins.
Decreased expression of the mutant CREBBP protein relative to
untransfected and non-targeted controls correlated with a
significant decrease in targeted mRNA, confirmed by qRT-PCR
(Figure 3). Knockdown of the mutant EP300 protein was similarly
demonstrated in immunoprecipitates (Figure 4). These results
confirm that the abnormal protein bands detected are mutated
variants of the CREBBP and EP300 proteins. This finding
indicates that certain MSI-derived mutant proteins are naturally
expressed at detectable levels.
Detection of additional potential mutant protein bands
In further Western Blot experiments (Figure 5), mutant TTK
protein bands were detected in multiple mutated cell lines at
Table 2. Representative cMS mutation analysis in colon cancer cell lines.
Gene BAX MSH3 TGFBR2 CASP5 MBD4 ACVR2A ACVR2A CREBBP EP300 AIM2 TTK PTHLH TCF7L2
cMS G8 A8 A10 A10 A10 A8 (1st) A8 (2nd) C5 A5 A10 A9 A11 A9
Cell line NMD-S NMD-S NMD-S NMD-S NMD-S NMD-S NMD-R NMD-R NMD-R NMD-R NMD-R NMD-R NMD-R
SW1222 wt wt wt wt wt wt wt wt wt wt wt - wt
SW480 wt wt wt wt wt wt wt wt wt wt wt wt wt
LIM1863 wt wt wt wt wt wt 21w t w t w t w t w t w t
LIM2099 wt wt wt wt wt wt wt wt wt wt wt wt wt
LIM2463 wt wt wt wt wt wt 21, wt wt wt wt wt wt wt
HT29 wt wt wt wt wt wt wt wt wt wt wt wt wt
HCA-7 21 21 21 +1, wt 21w t 21w t w t 21, wt wt 22, wt +1, wt
HCT116 21 21 21 21, wt 21, wt wt 21w t 21, wt 21, wt 21, wt 22w t
LoVo 21, +1w t 22, 21 21, wt wt wt 21 21, wt wt 21 21, wt 21 21, wt
LS174T 21w t 22, 21 21w t w t 21w t w t w t 21, wt 21, wt 21, wt
LIM1215 21 21, wt 21 21w t w t 21, wt wt wt 21, wt 21, wt 21w t
LIM1899 21w t 22, +1 21, wt 21, wt wt 21w t w t w t 21, wt 21, wt wt
LIM2405 wt 21, wt wt 22, 21w t 21 21, wt wt wt wt wt 21, wt wt
LIM2408 wt 21, wt wt 22, 21w t 21 21, wt wt wt 21, wt wt 21, wt 21, wt
LIM2537 21, wt wt 22, 21 22, wt 21, wt wt 21w t w t 22, 21 21, wt 21, wt wt
LIM2550 wt wt 21, wt 21, wt 21, wt wt 21w t w t 22, 21 21, wt 21, wt wt
LIM2551 wt wt 21 22, wt wt wt 21, wt wt wt 21, wt 21, wt 21, wt 21, wt
21=deletion of 1 base in cMS; wt=wild type. NMD-S: predicted NMD-sensitive mutant transcript; NMD-R: predicted NMD-resistant mutant transcript. ACVR2A: A8 (1
st)
and A8 (2
nd) refer to two separate cMS in order of coding sequence.
doi:10.1371/journal.pone.0016012.t002
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TTK protein (97 kDa), consistent with the predicted size
(Table 3). Attempts at siRNA knockdown of mutant TTK were
hindered by difficulty in resolving the mutant and normal protein
bands. An AIM2 band was detected at about 46 kDa in Western
blots on immunoprecipitates from whole cell lysates, consistent
the size detected in previous studies using this antibody[28].
AIM2 protein was detected in multiple non-mutated cell lines and
also in homozygous AIM2 mutant LoVo cells. The mutant and
wildtype AIM2 proteins are of similar predicted molecular
weights (39 kDa and 40 kDa respectively). Because NMD-
resistant transcripts often have a cMS in the last exon near the
C-terminus, mutant proteins will often be of similar size to normal
proteins. This makes validation of these mutant protein bands by
techniques used to confirm the CREBBP and EP300 bands more
difficult.
Mutant protein bands were not detected for all NMD-resistant
transcripts assessed. In the case of ACVR2A, protein bands were
detected at the expected molecular weights for both normal and
mutant protein, but in a non-specific manner that did not correlate
with the mutation data. Multiple protein bands were detected in
blots for TCF7L2, a gene with numerous alternatively spliced
transcripts[29], but no mutant proteins were identified that
correlated with the mutation data.
Genome-wide search for NMD-resistant transcripts as a
source of targetable proteins
Having established that NMD-resistant transcripts can give rise
to expressed MSI-derived mutant proteins, we sought to identify
additional cMS-containing genes likely to generate expressed
mutant proteins in MSI-High colon cancers that could serve as
therapeutic targets. Using a bioinformatic strategy, we performed
a genome-wide search for cMS-containing genes based on criteria
predicted to encode for NMD-irrelevant mutant transcripts[24],
which are intrinsically NMD-resistant (Table S2). We identified
1511 non-redundant mononucleotide cMS repeats $7 mer in
length (including hypothetical genes) predicted to generate NMD-
resistant mutant transcripts. This compares with 17,654 mononu-
cleotide cMS ($6 mer) identified (irrespective of NMD status) in a
previous study[17].
Genes were selected for cMS mutation analysis based upon
selection criteria likely to be important to utility as a targetable
protein. We limited the study to the 316 mononucleotide cMS
Table 3. Mutant C-terminal peptide sequences encoded for by frameshift mutations in (A) NMD-sensitive and (B) NMD-resistant
transcripts.
A.
Gene cMS MW(w.t.) MW(mut) a.a. Mutant neo C-terminus (21 DNA base pair frameshift)
TAF1B A11 68143 9547 25 TILKKAGIGMCVKVSSIFFINKQKP
TGFBR2 A10 64568 17931 34 SLVRLSSCVPVALMSAMTTSSSQKNITPAILTCC
CASP5 A10 49736 10813 25 QLRCWNTWAKMFFMVFLIIWQNTMF
MSH3 A8 128029 45890 31 RATFLLALWECSLPQARLCLIVSRTLLLVQS
BAX G8 21184 6394 18 RHPSWPWTRCLRMRPPRS*
MBD4 A10 66050 34937 3 KDH
IGF2R G8 274374 147290 26 TLAIRFISAPQPSSSTVTAAPSGQYF
ACVR2A A8(1) 57847 16870 53 TALKYIFVAVRAICVMKSFLIFRRWKSHSPLQIQLHLSHPITTSCSIPWCHLC
B.
Gene cMS MW(w.t.) MW(mut) a.a. Mutant neo C-termin us (21 DNA base pair frameshift)
ASTE1 A11 77091 74956 32 GRRNRIPAVLRTEGEPLHTPSVGMRETTGLGC
PTHLH A11 23942 22251 11 RKTTEEHIICN*
MARCKS A11 31553 15650 11 RSAFPSRSLSS
ACVR2A A8(2) 57847 49559 4 RGLF
C4orf6 T10 10498 9166 58 SCQLNLGRKEHAKIFTFFFQLDTMDGNPGELTLELQTLQIKQSQNALLPAGPLTQTPV
AIM2 A10 38953 40387 13 HREVKRTNSSQLV
TCF7L2 A9 65288 53863 22 SAFATYKVKAAASAHPLQMEAY*
EPHB2 A9 117488 120698 62 REWEKRKQILGGGGKYKEYFLKRILIRKAMTVLAGDKKGLGRFMRCVQSETKAVSLQLPLGR
TFE3 G8 61518 56928 43 DLPRMLPISSPLHRPQMPFWTCTFPATTWGTWETPSTWGWRTF
RGS12 C8 149587 145966 48 RSLPAGPSALPSPPSPSRRRAPPRSGRGSLRKWRPGASRRWRMSTWPS
TTK A9 97069 100952 38 GEKNDLQLFVMSDTTYKIYWTVILLNPCGNLHLKTTSL
PA2G4 A8 43785 43230 15 RRPPRLQRMPPVGKH
AIM2 A6 38953 37115 6 MEKNYS
CREBBP C5 265351 208941 8 LPSPNPHP
EP300 C5 264161 187834 8 TMTTKWRN
Mutant sequence commences from 1st difference compared to wild type protein after the mutated cMS. a.a.: amino acids in mutant sequence. MW: Predicted molecular
weight of wild type (w.t.) and mutant (mut) protein in Daltons.
*alternative transcripts for these genes generate mutant transcripts with a different reading frame, encoding for different mutant C-termini.
doi:10.1371/journal.pone.0016012.t003
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microsatellite length and likely mutation frequency. Significant
mutation rates (.40%) have been reported for some 8 mer
repeats[16]. Genes with short predicted neo-C-terminal protein
sequences (,10 amino acids) were excluded, as these are unlikely
to generate useful T cell epitopes for a range of common HLA
types, as is required to overcome MHC restriction. Excluding
hypothetical genes (prefix LOC or KIAA), 179 cMS-containing
genes satisfied our selection criteria (Table S3). Evidence for
protein expression in colon cancers of the shortlisted genes was
also sought as an additional selection criterion to indicate likely
expression of the mutant proteins. The Human Protein Atlas [30]
includes data showing protein expression in colorectal cancers by
immunohistochemistry. However, such data is unavailable for
many genes, due to dependance of IHC upon the availability of
suitable antibodies. Therefore, gene expression profiling data was
also used to identify genes with the highest mRNA expression
levels based upon data from two studies [31,32] of MSI and MSS
colon cancers (Figure S2).
Selected genes (Table 4) were screened for cMS mutations in a
panel of 5 MSI and 1 MSS cell lines and a subsequent panel of 6
MSI cell lines was tested if the initial screen revealed any cMS
mutations. Three genes (SFRS12IP1, MED8 and ASXL1) were
mutated in 6/11 (55%) of MSI-High cell lines and two genes
(FBXL3 and RGS12) were mutated in 5/11 (45%). Several genes
with lesser mutation rates were also identified (Table S4).
In silico epitope analysis for NMD-resistant transcript
derived mutant proteins
To be useful as therapeutic vaccine/immunotherapy targets, the
mutant proteins identified need to generate CTL epitopes for
common HLA types. In silico analysis using the publicly available
software such as SYFPEITHI has been previously identified new
CTL epitopes that were subsequently validated in functional
assays[26]. To identify which MSI-derived mutant proteins are
likely to be immunogenic, we assessed mutant proteins arising
from NMD-resistant transcripts for potential HLA-A*0201
epitopes. HLA-A*0201 is the most common HLA type, present
in about 50% of the population[33]. SYFPEITHI scores are based
upon binding motifs common to known naturally occurring
epitopes. According to the SYFPEITHI scoring guidelines, a
naturally expressed epitope should be amongst the top 2% of all
peptide scores assessed in 80% of cases[26]. We assessed mutant
C-termini arising from common NMD-R mutations (Table S5)
and the top 2% of HLA-A*0201 SYFPEITHI binding scores
generated from the mutant proteins were determined (Table 5).
The top-ranking peptides had SYFPEITHI binding scores ranging
from 23–31. These scores are comparable to the binding scores of
135 known HLA-A*0201 CTL cancer epitopes[26], including the
4 published MSI-derived epitopes, which have a median score of
24 and a mean of 23.4 (Table S6).
Based upon available reported cMS mutation rates for EPHB2,
TTK and RGS12 (C8), a vaccine including these three mutant
proteins will include at least one probable HLA-A*0201 epitope
for 69% of patients (12(1241%)x(1227%)x(1228%)). Further
HLA-A*0201 epitopes were identified for several genes
(TMEM97, ASXL1, SFRS12IP1, RGS12 (A9), RTKN2) with
common mutations in this study, indicating that also targeting
these genes could broaden HLA-A*0201 coverage. Some rare
mutations (e.g. NTAN1, RAPH1) also produce immunogenic
epitopes that would not provide broad population coverage, but
may also be worth targeting in selected patients.
Discussion
Microsatellite instability gives rise to predictable frameshift
mutations involving the cMS of many genes. Mutant proteins
arising from these mutations are a logical source of tumour-specific
antigens that could account for both the presence of increased
TILs and the better prognosis associated with an MSI-High
phenotype. This concept is supported by a recent finding of a
correlation between immune infiltrate density and the number of
cMS frameshift mutations detected in a set of MSI-High colon
cancers[34]. We have validated at least two examples (CREBBP
and EP300) of naturally expressed mutant proteins in MSI-High
colon cancer cell lines, both arising from NMD-resistant
transcripts. These findings confirm that NMD-resistant transcripts
can generate naturally expressed MSI-derived mutant pro-
teins[34,35]. The cMS repeats in CREBBP and EP300 are short
and unlikely to be mutated in a high proportion of MSI-High
tumours. However, it is likely that some common NMD-resistant
mutations such as TTK will also generate targetable mutant
proteins in MSI-High cancers. Our genome-wide strategy to
identify immunogenic NMD-resistant transcripts has identified five
novel cMS mutations (SFRS12IP1, MED8, ASXL1, FBXL3,
RGS12) in at least 45% of eleven MSI-High colon cancer cell lines
tested. Mutation analysis in a larger series of primary MSI-High
colon cancers will enable the mutation frequencies of these
potential therapeutic targets to be more accurately determined.
In vitro studies have identified CTL responses to synthetic
mutant peptides arising from common cMS mutations, using
peripheral blood mononuclear cells from patients with MSI colon
cancers[10,11,12,13,14,36] and intriguingly, also in healthy
individuals with HNPCC[15]. These studies have shown that
tumour-specific mutant proteins can stimulate in vitro T cell
immunity and support the concept of a vaccination strategy. The
published HLA-A*0201 CTL epitopes for TGFBR2[10,11],
CASP5[12], OGT[13] and U79260(FTO)[14] all arise from
NMD-sensitive mutant transcripts. NMD-inhibition experiments
have shown that mutant TGFBR2 is one of the most upregulated
transcripts, with 10-fold increased mRNA expression in one
study[27,37]. The T cell responses conflict with the expected
impact of NMD upon mutant protein expression. A transfection
study showed that mutant TGFBR2 protein is detectable in
transfectants of mutant cDNA (NMD-resistant), but not mutant
gDNA (NMD-sensitive)[35]. We did not detect mutant proteins
from NMD-sensitive transcripts (BAX, CASP5 and MSH3).
However, NMD is a translation-dependant process[24] and low-
level mutant protein expression from the initial round of
translation may be sufficient to stimulate immune responses.
CTL can show exquisite sensitivity to a specific peptide/HLA
ligand, with as few as 3 target peptide/MHC complexes being
sufficient for CTL-specific cell lysis in vitro[38]. Humoral responses
to mutant TGFBR2 protein have been identified by ELISA, but
only in a minority (10%) of MSI-High colon cancer patients[39].
Figure 1. Expression of normal BAX protein, but not mutant BAX protein by MSI-High cell lines. (A) Normal BAX protein (21 kDa, arrow),
but no mutant BAX protein (predicted 6.4 kDa) was detected in Western Blot analyses on whole cell lysates of colon cancer cell lines. Cell lines with
BAX G8 cMS mutation status: 1. LoVo (21, +1), 2. SW480 (wt), 3. HCA7 (21, wt), 4. LS174T (21), 5. HCT116 (21, wt), 6. HeLa (wt), 7. LIM1215 (21). (B)
Homozygous 21 base mutation in G8 cMS in LS174T cell line (top) compared to non-mutated cell line, SW1222 (bottom) (reverse DNA sequencing).
(C) Normal BAX protein (arrow), but no mutant BAX protein detected by immunoprecipitation: 1. HeLa (wt), 2. LS174T (21). IgG light chain at 25 kDa.
doi:10.1371/journal.pone.0016012.g001
Mutant Proteins Expressed by MSI-High Colon Cancer
PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e16012Mutant Proteins Expressed by MSI-High Colon Cancer
PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e16012A benefit of NMD-resistant transcripts as a source of targetable
mutant proteins is that stably expressed tumour antigens can be
cross-presented to the immune system by dendritic cells to stimulate
CTL and T helper cell responses[40]. Cross-presentation is likely to
result in superior anti-tumour immunity and NMD-resistant
transcripts as a source of targetable mutant proteins. A fusion-gene
assay reported a significant correlation between the expression of
transfected MSI-derived mutant proteins and cross-presentation of
co-expressed ovalbumin antigen [18]. For genes with negligible
detectable protein, some moderate to strong CTL responses were
detected, but without cross-presentation[18]. A limitation of the
transfection assay is that mutant cDNA constructs were used and
therefore the experiments did not evaluate the impact of NMD
upon mutant protein expression. Our approach overcomes this
through direct detection of mutant protein expression. A modified
transfection assay requiring natural splicing of the C-terminus could
also identify biologically relevant vaccination targets.
NMD-inhibition experiments have identified some ‘‘NMD-
escape’’ transcripts which partially resist degradation due to
NMD[27],. MBD4 is predicted generate an NMD-sensitive
transcript, but a faint abnormal protein band has been reported
in Western blot analyses of MBD4 mutated cell lines. This may
represent mutant MBD4 protein expression due to NMD-
escape[23]. NMD-escape transcripts may be a useful source of
protein targets, but these are unable be predicted and further work
is needed to determine which NMD-escape transcripts produce
targetable mutant proteins. Strategies that interfere with NMD
without inhibiting protein translation should cause a generalised
upregulation in NMD-sensitive mutant transcripts, unmasking a
range of tumour antigens. This approach could complement a
vaccine targeting MSI-High tumours by broadening the range of
available immune targets beyond NMD-resistant transcripts.
NMD-inhibition by siRNA targeting of NMD regulatory genes
SMG1 or UPF2 has recently been shown capable of inducing
Figure 3. Validation of mutant CREBBP protein. Specificity of the mutant protein band was confirmed by gene-specific knockdown in
transfectants of siRNA targeting CREBBP. (A) Detection of mutant protein band (black arrow) in whole cell lysates of LoVo cell line, but normal protein
only (white arrow) in non-mutated SW480 cell line. (B) Western Blot of LoVo whole cell lysates from siRNA SMARTpool transfectants show decreased
expression of normal (white arrow) and mutant (black arrow) CREBBP protein band in CREBBP-targeted lysates (lane 1). Beta-catenin loading control
(grey arrow) 92 kDa. (C) Relative intensity of normal (blue) and mutant (red) CREBBP protein bands compared to untransfected cells (PBS). (D)
Decreased CREBBP mRNA expression in CREBBP siRNA transfectants (left lane) relative to untransfected cells (right lane).
doi:10.1371/journal.pone.0016012.g003
Figure 2. Expression of mutant CREBBP and EP300 proteins, arising from NMD-resistant mutant transcripts. Normal proteins (white
arrow) and mutant proteins (black arrow) were detected in Western Blot analyses on whole cell lysates for (A) CREBBP and (B) EP300. (A) CREBBP C5
cMS: 1. SW480 (wt), 2. LoVo (21, wt), 3. HCT116 (wt), 4. LIM1215 (wt), 5. LS174T (wt). MW (kDa): wt 265, mut 209. (B) EP300 A5 cMS: 1. LoVo (wt), 2.
HCT116 (21, wt), 3. HCA7 (wt), 4. LIM1215 (wt), 5. LS174T (wt). MW (kDa): wt 223, mut 187.
doi:10.1371/journal.pone.0016012.g002
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with an NMD-sensitive target antigen[41].
Our confirmation of mutant protein expression by MSI-High
tumours may have important clinical applications. A vaccine
targeting commonly expressed mutant proteins has been proposed
as a promising strategy for the treatment of MSI-High tumours
[15,18,34,42]. With sufficient targets, vaccination may be feasible
provided that the mutant proteins are expressed, antigenic
epitopes are generated and antigen presentation is functional.
Further work is needed to determine which mutant protein
immune responses can confer a survival benefit to patients with
MSI-High tumours. Mutant proteins secreted into the serum could
serve as useful biomarkers for the early detection of MSI-High
tumours, particularly in the HNPCC affected population. Such
biomarkers would be a useful adjunct to colonoscopic screening,
since MSI-High colorectal cancers have a propensity for interval
adenomas and tumours developing in the period between
screening colonoscopies[43,44]. The common, predictable and
tumour-specific nature of MSI-derived mutant proteins makes
them ideal candidates as therapeutic targets or diagnostic markers.
Materials and Methods
Cell lines and culture
LIM colorectal cancer cell lines were established from tumour
biopsies at the Ludwig Institute for Cancer Research (LICR)
Melbourne Branch as described previously: LIM1215[45],
LIM1899[46], LIM1863[47], LIM2463[48] and (LIM2099,
LIM2405, LIM2408, LIM2537, LIM2550 and LIM2551) [49].
The LIM cell lines were established from both sporadic and
familial colorectal cancers[49] and can be obtained from CellBank
Australia (www.cellbankaustralia.com) or from the LICR Mel-
bourne Branch on completion of a standard academic materials
transfer agreement. SW1222 colorectal cancer cells were provided
by the Ludwig Institute for Cancer Research, New York Branch,
(New York, NY) and HCA7 colorectal cancer cells were obtained
from the European Collection of Cell Cultures (Porton Down,
UK). HCT116, LS174T, SW480, LoVo and HT29 colorectal
Figure 4. Validation of mutant EP300 protein. Specificity of the
mutant protein band confirmed by gene-specific knockdown in
transfectants of siRNA targeting EP300. (A) qRT-PCR data to assess
siRNAs targeting EP300 (best knockdown using P300-1 and P300-3). (B–
C) Decreased mutant EP300 protein detected in Western Blot analyses
on immunoprecipitates of EP300 siRNA transfectants relative to
untransfected controls (PBS).
doi:10.1371/journal.pone.0016012.g004
Figure 5. Potential mutant TTK and AIM2 proteins. (A) Western
blot analyses on whole cell lysates identified a potential mutant TTK
protein band (black arrow) in multiple mutated cell lines and normal
TTK protein (white arrow) only in non-mutated lines: 1. LIM1863 (wt), 2.
HCA7 (wt), 3. LIM1899 (21, wt), 4. HCT116 (21, wt), 5. LoVo (21, wt), 6.
LIM2537 (21, wt), 7. LIM2551 (21, wt). TTK MW (kDa): wt 97, mut 101.
(B) Western blot analyses on immunoprecipitates of whole cell lysates
identified an AIM2 protein band (black arrow) in all cell lines, including
the homozygous mutant LoVo cell line: 1. SW480 (wt), 2. LoVo (21), 3.
HCT116 (21, wt). 4, LS174T (wt). AIM2 MW (kDa): wt 39.0, mut 40.4.
doi:10.1371/journal.pone.0016012.g005
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from the American Type Culture Collection (Rockville, MD).
Cells were cultured at 37uC and 5% CO2 in RPMI 1640 media
(Invitrogen) supplemented with 10% foetal calf serum (FCS), 8 U/
ml insulin, 0.5 mg/ml hydrocortisone, 1610
22 mg/ml thiogly-
cerol, 20 mg/mL streptomycin sulfate and 12 mg/mL benzylpeni-
cilin or in DMEM media (Invitrogen) supplemented with 10%
FCS, 20 mg/mL streptomycin sulfate and 12 mg/mL benzylpeni-
cilin.
Assessment for MSI by immunohistochemistry (IHC)
Cell blocks of each cell line were prepared from 5610
7 cells,
rinsed and resuspended in 5 mL PBS, centrifuged into a pellet,
fixed in 10% neutral buffered formalin and embedded in
paraffin. Sections 3 mm thick were prepared using Superfrost
Plus Adhesion slides (Thermo Scientific). IHC for DNA
mismatch repair proteins was performed on the sections using
Vision Biosystems Bond-Max automated IHC stainer, with on-
board antigen retrieval using Bond Epitope Retrieval Solution 2
Table 4. NMD-R C-terminal peptide sequences from genome-wide search selected for mutation analysis.
Gene cMS MW(w.t.) MW(mut) a.a. Mutant neo-C-terminus (21 base pair frameshift)
SFRS12IP1 A10 18176 18253 66 GKGLTHPVPLKRTLQNKRNKNIRRKKRKKKKRVNQKKGNITKRKKRREKRKSILLHLIVLNSPESN
MED8 A9 32817 38899 61 MPTCSSGEAWACSPFHPLRSQLGFYLSNSHKVPYPLPHLIHTRLSQEVALPGRTMWERVFP
ASXL1 G8 165441 77046 57 VARVEVAAGPPMREVAEAAAVVMVVRPVATLSPGEARAPLESVRQIYSEHNYCRLIL
FBXL3 T9 48705 36034 24 YMKKNLTPSFAMKYLPPICTLGDQ
RGS12 A9 149587 132211 31 NIRKLIWTKQRSFLSLFPKLRATEQMTNVGC
RTKN2 A9 69301 59002 66 LKRQMGSSLLVSMKNPYHLLGPHSLMVTIKWSSRKRYCILQVSHYMMKKGKRDKLPFLLLINFHSA
RTN3 A8 27567 35071 66 RQNKYMETRNATVTKTPFNSYNVVTCTMKENTQCQLEPAFQAFFLIWCFLPSFPFNPQYQAQKLMD
SAFB2 C8 107469 111382 48 RTPTSPAATKSHSLRVFGWADALLNLVARVPSNLGDLFKSKVNPATML
TMEM97 A10 20847 41744 187 NEGNNHWPRVEMPTGWLLVGYNTRNTAQNPRLQQHLKHWQQCTRARWCQEPCQTLTFFHFFFFFKTVSLCCP…
TMEM97
(cont)
- - - - …GWSKGQWHDLGSLQPPPPGLKPSSLASQVARTTGVYQHVWLICFVFFVCVETGFCHVAQVGLERLGSSD…
TMEM97
(cont)
- - - - ……LPTSVSLSAGITDVNHWAQPKPSPSKGTGMNRPIGLRVGKGVWARL
ANKRD49 A9 27289 11639 31 WKKTQADCFFGLLKKIGLPQCGDSFLKRPLT
VRK2 A8 58138 43564 20 STVREALSPVQHGKCRKRRN
EAPP A8 32761 20412 54 RRNNTRFQQMTNYCMILKKITEIRPGLMHREGVTMVWDHRDHVNNSLFQIVMLS
NTAN1 A8 34676 40304 62 MKMACGKRSLLQEVKKHELPKKAPSWPDRPLVGLARIQIWILHLLGLRPPSLLSVFQMTFIK
RAPH1 C8 135250 86746 18 HLLLSLHPSLPKLPQNPL
CCKBR T8 48417 40685 34 CVGCQFIVPTRGAPLMARVHTEHSRVLLSPSFTC
P4HB A8 57114 57013 117 TSLWSSMPHGVVTANSWLPFGINWERRTRTMRTSSSPRWTRLPTRWRPSKCTASPHSSSFLPVPTGRSLITTGNA…
P4HB (cont) - - - - …RWMVLRNSWRAVARMGQGMMTISRTWKKQRSQTWRKTMIRKL
RAB40C C8 31303 36007 57 RTARGVTARSPSGDGRGRLCRCQEGSSWTLLAGRQASAAYVETVHTAASEAPGFPHT
ST8SIA6 A8 44834 34098 52 PYFWRTLQPMEMHFFFCQHFPSGPTRVPLSKYTTRSKSLKQDKRFYFSIPST
CIR A9 52311 38786 50 YKGRKERKTSVQGITTVILKRRTSLRRESFMKNFLAVTITGKKPRKSPGS
KCNC1 A8 57940 54089 19 RSIFRGHRSWDLPIIVNLS
SP100 A8 100413 90992 39 RSSRIPMHPRGLLWPFSCSALSIAQKSKENILACPLMML
C15orf48 A9 9617 7122 16 IQNLGKLWTLLYLKSL
DYRK3 A8 65711 37630 34 ISFRVLASSWYASLPSPSCNLWMPSTKIRLFTAI
ERCC5 A9 133103 110374 64 NYGHCNSPLAFLTQLLPRPTSNPWWMTRRDPFCGGNLISTKLENFVSGISAGTERRQMNLCFLY
GPATCH4 A8 42053 31346 72 RKRKGGRKRRKKLQHLKGMMQMRSTQNMLSRTSEKARRRKGDIKKERSQMKERVQLKGMRRRTLQEQVGLGN
HOXB7 G8 24014 17050 98 AWRARARPASTRPAMGSSRVPSTCTARPLSRTSPGCVPATPPRRRAPRSRGTRTWRPRVTSGSTPGCEAQELTA…
HOXB7
(cont)
- - - - …NEAARPTPATRPWSWRKNFTTIAT
INTS8 A8 113084 117050 43 SFSKQWQNFTFKQLNFFNFYFLNNGLKINSIKRLSLYNTYVHN
RARRES3 A8 18178 23706 55 RQPEAATKSCVRSSCGGPSGDEPPPCLQQPDPRALSQAFSRSFPLFPSLAGKSMI
SF3B2 A8 100223 104095 58 NGKLSPRTAVGAARNIRSSSFRSPHTSPFFGPTSGCLGFTQEPPLPQFPRTCHFMFLF
TCERG1 A8 123896 114436 40 SLRKILDVLSSPPVTGKNKENLKNISETNISQPKLTSGRF
WHSC1 C8 152252 154227 48 QSQGSRRGRGGGGGAGGESQRANSARRPLGRIQGRCRAAGPACGRGRA
ZNF133 A8 73315 20485 120 NVHRQPVQIQSQSSTSILSALRVSPVRNSPCSMCCVIIPPGSSHACVQKVTSSLGIRAQGTRRSSNKPLRGDPGV…
ZNF133
(cont)
- - - - …IKQKVLREKVPCLCLEEPRKGLWERSPGHPRGSQSALGTASEGWS
doi:10.1371/journal.pone.0016012.t004
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Detection kit DS9713 and the following primary antibodies:
MLH1 (Novocastra: NCL-L-MLH1), MSH2 (Oncogene: NA27),
MSH6 (BD Transduction Laboratories: 970220-150) and PMS2
(BD Pharmingen: 556414). An anatomical pathologist (DSW)
interpreted the IHC stained sections. Cell lines with nuclear
staining for DNA MMR proteins were interpreted to have a
normal expression pattern (likely MSS) and cell lines lacking
nuclear expression of one or more DNA MMR proteins were
interpreted as having MSI.
Table 5. HLA-A*0201 SYFPEITHI [26] scores of (A) top ranking NMD-R derived epitopes compared with (B) published MSI-derived
epitopes.
A
GENE HLA-A*0201 epitopes SCORE Reported (%) This study (%)
RAPH1 S L H P S L P K L 31 No data 18
RAPH1 L L L S L H P S L 28 No data 18
RAPH1 H LLLSLHPSL 2 5 N od a t a 1 8
RAPH1 S L P K L P Q N P L 23 No data 18
NTAN1 G L R P P S L L S V 30 No data 18
NTAN1 L L Q E V K K H E L 27 No data 18
NTAN1 G L A R I Q I W I L 27 No data 18
NTAN1 H L L G L R P P S L 27 No data 18
NTAN1 K M A C G K R S L 25 No data 18
NTAN1 L L G L R P P S L 25 No data 18
NTAN1 Q I W I L H L L G L 25 No data 18
NTAN1 R I Q I W I L H L 23 No data 18
NTAN1 R I Q I W I L H L L 23 No data 18
T M E M 9 7 SLSAGITDV 2 8 1 1 3 6
T M E M 9 7 SLQPPPPGL 2 7 1 1 3 6
TMEM97 W L I C F V F F V 27 11 36
T M E M 9 7 SLASQVART 2 4 1 1 3 6
ASXL1 V M V V R P V A T L 27 No data 55
ASXL1 M V V R P V A T L 23 No data 55
EPHB2 I L I R K A M T V 27 41 36
EPHB2 V L A G D K K G L 25 41 36
EPHB2 I L I R K A M T V L 24 41 36
T T K LLNPCGNLHL 2 6 2 7 7 0
TTK I L L N P C G N L 25 27 70
TTK N L H L K T T S L 25 27 70
TTK K I Y W T V I L L 24 27 70
TTK V M S D T T Y K I 23 27 70
SFRS12IP1 S I L L H L I V L 26 No data 55
RGS12 (A9) S L F P K L R A T 25 No data 46
RGS12 (C8) S L P A G P S A L 25 28 18
RTKN2 H L L G P H S L M V 25 No data 36
RTKN2 L L G P H S L M V 25 No data 36
EAPP M I L K K I T E I 25 No data 18
EAPP C M I L K K I T E I 24 No data 18
EAPP L M H R E G V T M V 24 No data 18
B
GENE HLA-A*0201 epitopes SCORE Reference
FTO (U79620) TLSPGWSAV 25 [14]
OGT SLYKFSPFPL 23 [13]
CASP5 FLIIWQNTM 20 [12]
TGFBR2 RLSSCVPVA 19 [10,11]
doi:10.1371/journal.pone.0016012.t005
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Cell lines were tested for frameshift mutations in a selection of
cMS reported to be mutated in MSI-High colon cancers by DNA
sequencing (TGFBR2, BAX, CASP5, TCF7L2, TAF1B, MSH3,
IGF2R, CREBBP, EP300, MARCKS, AIM2, ACVR2) or by
fragment analysis (ASTE1, PTHLH, C4orf6, EPHB2, TFE3,
TTK, PA2G4, KCNC1, SP100, FBXL3, MED8, RGS12, CIR).
Genomic DNA was extracted from the cell lines with Qiagen
DNeasy Blood & Tissue Mini Kit (Qiagen) using standard
protocols. PCR primers (Figure S7) were designed to flank the
cMS of interest, yielding amplimers 100–800 base pairs in length
(for DNA sequencing) or 90–200 base pairs in length with FAM
tags located at the 59 end of the 59 oligonucleotides (for fragment
analysis). PCR reactions were performed in 25 mL total volume,
with 100 ng gDNA, 2.5 mL1 0 6 reaction buffer, 1 mM MgCl2,
100 mM dNTPs, 200 mM of each primer and 0.5 U Taq DNA
polymerase, using the following standard conditions: initial
denaturation at 94uC for 3 min, 35 cycles (denaturation at 94uC
for 30 sec, annealing at 58uC for 30 sec and primer extension at
72uC for 1 min). A final extension step was performed at 72uC for
10 min. PCR fragments were resolved by agarose gel electropho-
resis with ethidium bromide and visualised with ultraviolet light.
Gel extractions were performed to purify PCR fragments (Qiagen)
prior to DNA sequencing, using 5 ng DNA per 100 base pairs of
template and 3.2 pmol of forward or reverse primer in 10 ml
ddH2O (Wellcome Trust Sequencing Centre, Monash Medical
Centre, Victoria, Australia). DNA sequencing data was analysed
using Chromas Version 2.33 (Technelysium) and assessed for cMS
frameshift mutations. DNA sequencing data from MSS cell lines
were used as controls to indicate the degree of PCR slippage
artefact affected the normal cMS sequences. For fragment
analysis, PCR products were diluted based upon assessment of
the intensity of the bands detected in the DNA agarose gel, loaded
into 96 well plates with 2 mL sample, 9.75 mL formamide and
0.25 mL LIZ size standard per well for analysis. Samples were
denatured at 95uC for 3 minutes, incubated on ice for 1 minute
and loaded into a sandwich for analysis. Data was analysed using
Gene Mapper 4.0 software (Applied Biosystems). Samples from
MSS cell lines were used as controls to indicate the normal
fragment size and pattern of non-mutated cMS.
Prediction of mutant proteins arising from frameshift
mutations
Genetic sequences were accessed from Ensembl[50] (latest
release 58 – May 2010) and transcripts were assessed for the
presence of the described cMS. Normal protein sequences and
mutant protein sequences expected to arise from a frameshift
mutation of 21 DNA base pair were determined for each cMS-
containing transcript using ExPasy Translate Tool and the
predicted molecular weight of the normal and mutant proteins
were calculated with the ExPasy Compute pI/Mw Tool (Swiss
Institute of Bioinformatics)[51].
Western blotting
Whole cell lysates were prepared by incubation (15 min) of 10
6
cells per 50 mL ice-cold RIPA lysis buffer (20 mM Tris-HCl
(pH 7.2), 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% Triton
X-100, 0.5% deoxycholate, 0.1% SDS, 1 mM DTT, 16complete
protease cocktail (Roche)). Cell debris was pelleted by ultra-
centrifugation (10
5 rpm, 30 min, 4uC). Immunoprecipitates were
prepared by incubation for 2 hours of the lysates with Protein A-
sepharose beads pre-coupled to primary antibodies (Table 6A).
Whole cell lysates or immunoprecipitates were resuspended in
sample buffer (2% SDS, 20% glycerol, 0.1 M TRIS pH 6.8,
50 mM TCEP bond breaker (Pierce), 0.004% bromophenol blue),
boiled (5 min) and size-fractionated by SDS-PAGE using the Mini
Protean system (BioRad, USA) and a 3–8% Tris-Acetate gel
(NuPAGE Tris-acetate running buffer, Invitrogen, USA) for larger
proteins (.150 kDa) or 4–12% Bis-Tris gel (NuPAGE MES
running buffer, Invitrogen, USA) for smaller proteins. Gels were
transferred (100 V, 4uC, 3 hrs) to a PVDF membrane (Millipore)
Table 6. Primary antibodies (A) and secondary antibodies (B) used in western blot +/2 immunoprecipitation experiments.
A. Primary antibodies.
Antigen Product (clone) Species Epitope Dilution Manufacturer
AIM2 (3B10)[28] Mouse mAb a.a. 1–186 1/10 Peter MacCallum Cancer Centre*
BAX B8554 (2D2) Mouse mAb a.a. 3–16 1/2000 Sigma-Aldrich
BAX ab7977 Mouse pAb a.a. 11–30 1/100 Abcam
CASP5 ab40887 (EP876Y) Rabbit N-terminus 1/4000 Abcam
CREBBP sc-689 Rabbit N-terminus 1/200 Santa Cruz
CREBBP MAB1133 Mouse Unknown 1/200 Chemicon
CTNNB 610153 Mouse a.a. 571–781 1/5000 BD Transduction Laboratories
EP300 sc-584 Rabbit N-terminus 1/200 Santa Cruz
EPHB2 sc-28980 (H-80) Rabbit pAb a.a. 255–334 1/100 Santa Cruz
MSH3 611390 (50) Mouse a.a. 136–349 1/200 BD Transduction Laboratories
TTK N1 (sc-56968) Mouse mAb a.a. 3–856 1/50 Santa Cruz
B. Secondary antibodies.
Antigen Antibody name Species Dilution Manufacturer
Mouse Ig Anti mouse Ig odyssey 680 labelled Donkey 1/10000 Li-Cor
Rabbit Ig Anti rabbit Ig odyssey 680 labelled Goat 1/5000 Li-Cor
*3B10 Hybridoma supernatant kindly donated by Dr Ricky Johnstone, Peter MacCallum Cancer Institute.
doi:10.1371/journal.pone.0016012.t006
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(v:v)), blocked overnight (5% skim milk powder, 0.02% azide),
incubated with the primary antibody (1 hr), washed in PBS with
0.1% Tween-20 (PBST), incubated with the appropriate second-
ary antibody (Table 6B) for 1 hour and washed again. Membranes
were imaged using the Odyssey Infrared Imaging System (LI-
COR Biosciences).
RNA interference (RNAi) assays
Transient transfectants of cell lines were prepared using
individual or SMARTpool preparations of small interfering
RNA (siRNA) (Thermo Fisher Scientific), targeting the genes of
interest. Transfectants of non-targeting (scrambled) siRNA and no
siRNA (PBS only) were used as negative controls. Lipofectamine
(7.5 ml) incubated with 250 ml OPTI-MEM media (Invitrogen) per
transfection for 7 min was combined with siRNA (50 pmol in
250 ml OPTI-MEM per transfection) for 20 min at RT and added
to cells pre-plated in 2 mL antibiotic-free OPTI-MEM media (6
well plates, LoVo 15610‘5/well, HCT116 10610‘5/well). After
incubation overnight the siRNA-containing media was removed
and replenished. At 24 hours post-transfection cell samples were
split, one-third into fresh 6 well plates with 2 mL media/well for
Western blot analysis and the remainder into 10 cm dishes and
resuspended in 10 mL media/dish for qRT-PCR analysis. At
72 hours cells were harvested, counted using Countess Automated
cell counter (Invitrogen) and lysed. Samples for Western blot
analyses were stored at 280uC until ready for analysis. Specificity
of candidate normal and mutant protein bands in western blots
was confirmed by detection of decreased protein band intensity in
lysates of cells transfected with siRNA targeting the gene of interest
relative to negative controls. Blots were probed for a non-targeted
gene (b-catenin) as a loading control to enable the relative ‘‘knock-
down’’ to be calculated.
Extracts of total RNA for qRT-PCR were prepared from
transfectants using RNAspin Mini RNA isolation kit (GE
Healthcare) using standard protocols at room temperature. RNA
concentration and quality (A260/280 ratio) was assessed with a
NanoDrop ND-100 Spectrophotometer (Thermo Scientific). RNA
samples were stored at 280uC until ready for analysis. Samples
were digested using RNase free DNase and converted to cDNA
with an RT kit (Applied Biosystems). Residual RNA was digested
with RNAase. Serially diluted cDNA samples were analysed in
duplicate by qRT-PCR with an ABI 7300 Real Time PCR
instrument (Applied Biosystems), using Taqman (ABI) Master
Mix, primers/probes for the gene of interest and for a control gene
(GAPDH). No primer/probe, no RT enzyme and no cDNA
negative controls were included and a standard curve was
generated from the data. Fold-change in transfectant mRNA
expression levels relative to untransfected cells was evaluated using
the comparative CT (DDCT) method, expressed as a range
incorporating the standard deviation of DDCT. Gene-specific
knockdown in siRNA transfectants was confirmed by detecting a
significant decrease in mRNA levels of transfectants relative to
untransfected cells.
Nano-Liquid Chromatography-Mass Spectrometric
Analysis
Immunoprecipitates of cell lysates (5610
8) were produced lysed
and size fractionated by SDS-PAGE as described above. Gels for
mass spectrometry analyses were stained (1 hr) with Coomassie R-
250 (Pierce) and de-stained (.1 hr) in distilled water. Gel sections
(1.5 mm) were excised with a scalpel, extensively washed in
deionized water and digested with trypsin (0.25 mg) using a robotic
workstation (MassPrep, Micromass). Tryptic digests were concen-
trated to ,10 mL by centrifugal lyophilization (Savant) in
preparation for Electrospray-Ion Trap (ESI-IT) tandem mass
spectrometry (MS/MS) (LCQ-Deca, Finnigan). Digests (,10 mL
in 1% (v/v) formic acid) were transferred into 100 mL glass
autosampler vials for injection and fractionation by nano-reversed-
phase-HPLC (Agilent Model 1100 capillary HPLC) using a
15060.15 mm I.D. RP-capillary column (Reprasil-Pur, C18-AQ,
3 mm, Dr Maisch, GmbH), linear 60 min gradient from 0%–
100% Solvent B, flow rate of 0.8 mL/min at 45uC. Solvent A was
0.1% (v/v) aqueous formic acid and Solvent B was 0.1% aqueous
formic acid/60% (v/v) acetonitrile. The capillary HPLC was
coupled on-line to an ESI-IT mass spectrometer for automated
MS/MS analysis of individually isolated peptide ions. Raw MS/
MS spectra were extracted using Extract-MSN in Bioworks 3.1
(Finnigan, San Jose, U.S.A.). Parameters used to create the peak
lists were: minimum mass 400; maximum mass 5000; grouping
tolerance 1.5; intermediate scans 1; minimum group count 1;
automated calculation of charge state; 30 peaks minimum per
spectrum; peptide charge states 1+,2 + or higher; 62 Da peptide
mass tolerance; 60.5 Da MS/MS fragment mass tolerance.
Parent ion masses were determined based upon the isotope cluster
spacing in the zoom scan spectrum and individual spectra files
(.dta file extension) were generated. Acquired MS/MS spectra
were searched against the non-redundant protein subset database
(Ludwig NR_subset version_Q407) using the Mascot
TM search
algorithm (v2.1, Matrix Science, U.K.). Searches were conducted
with carboxymethylation of cysteine as a fixed modification
(+58 Da), variable oxidation of methionine (616 Da) and an
allowance for up to 3 missed tryptic cleavages. Results containing
possible peptide identifications by the Mascot algorithm were
validated manually.
Bioinformatic search for NMD-resistant mutant
transcripts
Coding microsatellite (cMS) containing sequences likely to be
NMD-resistant upon mutation were identified using a computer
program written in the Python language (http://www.python.org)
using the BioPython library of Python functions (http://biopython.
org). Matched human genomic DNA, mRNA and coding DNA
sequence (CDS) gene information was obtained from the RefSeq
database (NCBI build 37.1; ftp://ftp.ncbi.nih.gov/genomes/H_
sapiens/). The Python program processes each CDS entry,
determines the coding DNA sequence and translates this sequence
into a predicted amino acid sequence. Potentially erroneous CDS
entries are discarded if they generate sequences lacking an initial
methionine residue or a terminal stop codon. CDS entries
generating sequences with a premature stop codon are also
discarded. Retained CDS are checked for the presence of
mononucleotide cMSs at least six bases in length (e.g. AAAAAA).
One or two bases are deleted from the mononucleotide cMS and
translatedtogenerateaminoacidsequencesforthemutantproteins.
If a premature stop codon in the frameshift mutated sequence is
.55 bases upstream of the last exon-exon junction, this cMS is
excluded from further consideration, as the mutant mRNA is likely
tobe NMD-sensitive.Ifa premature stop codon isinthe last exon or
within 55 bases of the last exon-exon junction, the cMS is retained,
since the mutant mRNA is likely to be NMD-resistant. If no
premature stop codon is generated, then frameshifted DNA
sequence of the non-coding 39 end of the corresponding mRNA
entry is assessed for the presence of a stop codon. DNA sequences
lacking a stop codon are discarded, since the entire sequence is
unable to be characterized. Predicted mutant DNA and amino acid
sequences are characterized by length and site of the cMS repeat,
type of deletion (one or two repeat units) and the length, molecular
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proteins. The presence of any additional cMS in the genetic
sequencesisalsoidentifiedtodetectanylengthy59 cMS that maybe
susceptible to mutation and prevent some NMD-resistant tran-
scripts from being generated. The program also assesses genes for
dinucleotide cMS repeats using a similar algorithm.
Identification of new target genes
Genes from the genome-wide search were prioritized for study
based upon multiple criteria including susceptibility to frequent
frameshift mutation, likely antigenicity and likely protein
expression in colon cancer. A minimum mononucleotide cMS
length of eight nucleotides was chosen, since mutation rates in our
desired range (.30%–50%) have been reported for cMS of this
length in some genes, but not for shorter cMS[16]. Genes with
,10 amino acids of novel protein sequence were excluded, since
these sequences are unlikely to generate a range of useful CTL
epitopes. Immunohistochemical data regarding protein expres-
sion in colon cancer is available for some genes in the Human
Protein Atlas[30]. In the absence of such data for many genes,
gene expression microarray data were also used to assess which
genes are highly expressed in MSI colorectal adenocarcinomas.
Using two gene expression data sets that compared MSI with
MSS colon cancers using the same Affymatrix chip (PMID:
17047040, GEO entry GSE4554[31], PMID: 19088021, GEO
entry GSE13294[32]), we ranked shortlisted genes (NMD-
resistant transcripts, $8m e rc M S ,$10 amino acids of novel
mutant C-terminus) by median gene expression values. Genes
with either moderate to strong protein expression in colon cancer
in the Human Protein Atlas resource or with median values in the
top 50 scores by either gene expression study were considered for
cMS mutation analysis. Gene expression data does not necessarily
indicate relative expression between different proteins, since
factors such as hybridization efficiency influence the microarray
expression read-out (evident in the variability in expression values
between different probes for the same gene). However, there is
some correlation between gene expression and protein expression
and it is likely that high gene expression will correlate with protein
expression.
To identify new cMS mutations, PCR primers were designed to
amplify cMS-containing regions of the selected genes (Supple-
mentary Data 1). PCR and DNA sequencing was performed using
protocols described above. Five MSI-High colon cancer cell lines
(HCT116, LoVo, LIM1215, LS174T and HCA7) and one MSS
cell line (SW480) were initially screened for frameshift mutations
in the selected genes. Genes bearing mutations in this initial screen
were also tested for mutations in the remaining 6 MSI colon
cancer cell lines.
In silico T cell epitope prediction
Mutant proteins predicted to be generated from common cMS
mutations were screened for likely HLA-A*0201 CTL epitopes,
using the publicly available predictive software, SYF-
PEITHI[26]. This program uses a scoring system based upon
the binding motifs of known CTL epitopes to generate binding
scores that rank all potential nonamer and decamer peptides
generated from the input protein sequences in order of likely
binding to the HLA-A*0201 molecule. Peptides with scores in the
top 2% of peptides were identified as likely CTL epitopes, the
scores of which were validated by comparison with score of 133
known HLA-A*0201 CTL epitopes listed on the SYFPEITHI
website[26] and 2 MSI-derived HLA-A*0201 epitopes[13,14]
n o tl i s t e da tt h i ss i t e .
Supporting Information
Figure S1 Proteomic analysis for CREBBP and EP300.
(A) Immunoprecipitates of SW480 (wild type CREBBP) and LoVo
(21, wt) cell lines were prepared using anti-CREBBP antibody
and (B) immunoprecipitates of LIM1215 (wild type EP300) and
HCT116 (21, wt) cell lines were prepared using anti-EP300
antibody. Tryptic digests were prepared from the region of the gel
including the suspected CREBBP and EP300 bands. Tandem
mass spectrometry revealed multiple peptide sequences corre-
sponding to CREBBP in the SW480 cell line and EP300 in the
LIM1215 cell line, confirming the specificity of the wild type
protein band. Mutant protein bands were not confirmed by this
technique, possibly due to the presence of more abundant co-
immunoprecipitated proteins such as MYH9 (data not shown).
(DOCX)
Figure S2 Gene expression to prioritise target gene
selection. NMD-R transcripts with cMS $8 mer and mutant C-
terminus $30 a.a. and CREBBP were assessed using colorectal
cancer gene expression data from two studies. Boxplots of top 50
gene expression levels shown, with interquartile range above non-
specific background (set at 6). High gene expression was used to
indicate likely protein expression.
(DOC)
Table S1 Coding microsatellite (cMS) sequencing data
for genes with previously reported cMS mutations.
(XLS)
Table S2 a. Genes with mononucleotide cMS predicted to
generate NMD-resistant transcripts (21 base cMS frameshift
mutation). b. Genes with mononucleotide cMS predicted to
generate NMD-resistant transcripts (22 base cMS frameshift
mutation). c. Genes with dinucleotide cMS predicted to generate
NMD-resistant transcripts (21 repeat cMS fraemshift mutation).
d. Genes with dinucleotide cMS predicted to generate NMD-
resistant transcripts (22 repeat cMS frameshift mutation).
(XLS)
Table S3 Genes with at least 8 mer cMS predicted to
generate NMD-resistant transcripts with mutant C-
terminus at least 10 amino acids in length.
(XLSX)
Table S4 Coding microsatellite (cMS) sequencing data
for genes selected from genome-wide search for NMD-
resistant transcripts.
(XLS)
Table S5 NMD-R transcripts assessed for potential
HLA-A*0201 epitopes.
(XLSX)
Table S6 Syfpeithi binding scores for known HLA-
A*0201 ligands.
(XLSX)
Table S7 PCR primer details.
(XLSX)
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